Use: Labeled indications
- The treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure
- Use as an add-on therapy for the treatment of hypertension, to lower blood pressure.
- The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of…
- Treatment of primary hyperaldosternism for
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ALDACTONE is an aldosterone antagonist indicated for:
- The treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1).
- Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2).
- The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3).
- Treatment of primary hyperaldosternism for: (1.4) o Short-term preoperative treatment o Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia 1.1 Heart Failure ALDACTONE is indicated for treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. ALDACTONE is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension ALDACTONE is indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome ALDACTONE is indicated for the management of edema in the following settings:
- Cirrhosis of the liver when edema is not responsive to fluid and sodium restriction.
- Nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. Because it increases serum potassium, ALDACTONE may be useful for treating edema when administration of other diuretics has caused hypokalemia. 1.4 Primary Hyperaldosteronism ALDACTONE is indicated in the following settings:
- Short-term preoperative treatment of patients with primary hyperaldosteronism.
- Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery.
- Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).
Contraindications
- Hyperkalemia
- Addison's disease
- Concomitant eplerenone
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS ALDACTONE is contraindicated in the patients with: • Hyperkalemia • Addison's disease • Concomitant use of eplerenone ALDACTONE is contraindicated in patients with (4): ▪ Hyperkalemia ▪ Addison's disease ▪ Concomitant use of eplerenone
Dosing: Adult
- Heart failure (NYHA III-IV, reduced EF), K ≤5.0 mEq/L and eGFR >50: 25 mg once daily; may increase to 50 mg once daily
- Hypertension (add-on): 25 to 100 mg daily in single or divided doses
- Edema (cirrhosis, nephrotic syndrome): 100 mg daily; start in hospital for cirrhosis and titrate slowly
- Primary hyperaldosteronism: 100 to 400 mg daily before surgery
- Heart Failure: Initiate treatment at 25 mg once daily (2.2).
- Hypertension: Initiate treatment at 25 to 100 mg daily in either single or divided doses (2.3).
- Edema: Initiate therapy in a hospital setting and titrate slowly. The recommended initial daily dose is 100 mg in single or divided doses (2.4).
- Primary hyperaldosteronism: Initiate treatment at 100 to 400 mg in preparation for surgery. In patients unsuitable for surgery use the lowest effective dosage determined for the individual patient (2.5).
2.1 General Considerations
2.1 General Considerations ALDACTONE can be taken with or without food, but should be taken consistently with respect to food [see Clinical Pharmacology (12.3)].
2.2 Treatment of Heart Failure
2.2 Treatment of Heart Failure In patients with serum potassium ≤5.0 mEq/L and eGFR >50 mL/min/1.73 m², initiate treatment at 25 mg once daily. Patients who tolerate 25 mg once daily may have their dosage increased to 50 mg once daily as clinically indicated. Patients who develop hyperkalemia on 25 mg once daily may have their dosage reduced to 25 mg every other day [see Warnings and Precautions (5.1)].
In patients with an eGFR between 30 and 50 mL/min/1.73 m², consider initiating therapy at 25 mg every other day because of the risk of hyperkalemia [see Use in Specific Populations (8.6)].
2.3 Treatment of Essential Hypertension
2.3 Treatment of Essential Hypertension The recommended initial daily dose is 25 to 100 mg of ALDACTONE administered in either single or divided doses is recommended. Dosage can be titrated at two-week intervals. Doses greater than 100 mg/day generally do not provide additional reductions in blood pressure.
2.4 Treatment of Edema
2.4 Treatment of Edema In patients with cirrhosis, initiate therapy in a hospital setting and titrate slowly [see Use in Specific Populations (8.7)]. The recommended initial daily dosage is 100 mg of ALDACTONE administered in either single or divided doses, but may range from 25 to 200 mg daily. When given as the sole agent for diuresis, administer for at least five days before increasing dose to obtain desired effect.
2.5 Treatment of Primary Hyperaldosteronism
2.5 Treatment of Primary Hyperaldosteronism Administer ALDACTONE in doses of 100 to 400 mg daily in preparation for surgery. For patients who are considered unsuitable for surgery, ALDACTONE can be used as long-term maintenance therapy at the lowest effective dosage determined for the individual patient.
Dosing: Altered kidney function
Spironolactone raises the risk of high potassium (hyperkalemia), especially with kidney impairment. For heart failure the US label starts 25 mg daily at an estimated glomerular filtration rate (eGFR) above 50 and suggests 25 mg every other day at eGFR 30 to 50; it is contraindicated with existing hyperkalemia.
Kidney function measure: Heart-failure dosing uses eGFR (mL/min/1.73 m2).
Show full dosing details
- eGFR ≥60
- Heart failure (K ≤5.0 mEq/L, eGFR >50): 25 mg once daily, may increase to 50 mg (label). Other indications per label.
- eGFR 30–59
- eGFR >50: as above. eGFR 30–50: consider starting 25 mg every other day (heart failure; label). Monitor potassium closely.
- eGFR 15–29
- No dosing in label. High hyperkalemia risk: avoid or use with specialist input.
- eGFR <15 (not on dialysis)
- No dosing in label. Avoid or use with specialist input.
- Hemodialysis (intermittent)
- No data in label. In maintenance dialysis, two randomized trials (ACHIEVE, ALCHEMIST; 2025) found that spironolactone 25 mg daily did not reduce cardiovascular death or heart failure hospitalization, and the updated meta-analysis found no mortality benefit. Do not start it for cardiovascular protection; otherwise avoid or use with specialist input.
- Peritoneal dialysis
- No data in label. In maintenance dialysis, two randomized trials (ACHIEVE, ALCHEMIST; 2025) found that spironolactone 25 mg daily did not reduce cardiovascular death or heart failure hospitalization, and the updated meta-analysis found no mortality benefit. Do not start it for cardiovascular protection; otherwise avoid or use with specialist input.
- CRRT
- No data in label.
- Dialyzable? Not stated in label.
- Monitoring Serum potassium within 1 week of starting and regularly; kidney function and volume status; contraindicated with hyperkalemia, Addison's disease, eplerenone (label). Avoid potassium supplements and potassium-containing salt substitutes unless monitored (label 5.1).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Not established in children.
- eGFR 30–59
- Not established in children.
- eGFR 15–29
- Not established in children.
- eGFR <15 (not on dialysis)
- Not established in children.
- Hemodialysis (intermittent)
- Not established in children.
- Peritoneal dialysis
- Not established in children.
- CRRT
- Not established in children.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Dosage and administration (renal excerpts) US FDA label
2.2 Treatment of Heart Failure In patients with serum potassium ≤5.0 mEq/L and eGFR >50 mL/min/1.73 m 2 , initiate treatment at 25 mg once daily.
In patients with an eGFR between 30 and 50 mL/min/1.73 m 2 , consider initiating therapy at 25 mg every other day because of the risk of hyperkalemia [see Use in Specific Populations (8.6) ].
Dosing: Pediatric
- Approved ages
- Safety and effectiveness not established in pediatric patients (label).
- Usual dose
- Not established.
- Maximum dose
- Not applicable.
- Neonates
- Neonates: not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use ALDACTONE is substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, monitor renal function.
Dosage forms
Philippines
- Tablet: 25 mg, 50 mg, 100 mg
- Film-coated tablet: 25 mg, 50 mg, 100 mg
Registered products in the Philippines
53 products registered with the Food and Drug Administration (FDA) Philippines list Spironolactone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products53
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AldactoneSpironolactone | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Piramal Healthcare (UK) Ltd.United Kingdom | Pfizer, Inc. | DRP-2014 | Nov 17, 2029 | |
AldactoneSpironolactone | 25 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Piramal Healthcare (UK) Ltd.United Kingdom | Pfizer, Inc. | DRP-2016 | Nov 10, 2029 | |
AldactoneSpironolactone | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Piramal Healthcare (UK) Ltd.United Kingdom | Pfizer, Inc. | DRP-2013 | Nov 10, 2029 | |
AldaxSpironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | The Cathay YSS Distributors Co., Inc.Importer: Pharmakon Biotec Inc. | DRP-7359-12 | Oct 4, 2031 | |
AldaxSpironolactone | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | The Cathay YSS Distributors Co., Inc.Importer: Pharmakon Biotec Inc. | DRP-7361-07 | Oct 4, 2031 | |
AtagonSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | United Pharma Plus (Unipharma) Inc.Importer: Ambica International Corporation | DRP-4662-04 | Sep 3, 2028 | |
BeralactoneSpironolactone | 25 mg TabletClear Glass Vial x 100's (Box of 1's) | RxVAT-exempt | The Searle Company LimitedPakistan | Beracah Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-3826-01 | Jul 9, 2027 | |
CorlactoneSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's ((Box of 100's)) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4662-01 | Sep 3, 2028 | |
DiulactoneSpironolactone | 100 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 10's) | RxVAT-exempt | The Searle Company LimitedPakistan | Ambica International Corporation | DRP-3825 | Jul 9, 2032 | |
DiulactoneSpironolactone | 25 mg TabletClear Glass Vial x 100's (Box of 1's) | RxVAT-exempt | The Searle Company LimitedPakistan | Central West MarketingImporter: Ambica International Corporation | DRP-3826 | Jul 9, 2027 | |
DixspiroSpironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-7359-08 | Oct 4, 2031 | |
FaractonSpironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | MAGBRO HEALTHCARE PVT. LTD.India | Pharmakon Biotec Inc. | DRP-18888 | Sep 24, 2031 | |
FaractonSpironolactone | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | MAGBRO HEALTHCARE PVT. LTD.India | Pharmakon Biotec Inc. | DRP-18887 | Sep 24, 2031 | |
GolactoneSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-4662-07 | Sep 3, 2028 | |
HairosSpironolactone | 25 mg TabletAlu/PVC blister pack x 10’s (Box of 100’s) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Greencore Pharma Inc.Importer: Next Chemical Enterprises | DRP-7714-01 | Nov 15, 2031 | |
LactoneSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-4662 | Sep 3, 2028 | |
Lactone-100Spironolactone | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Ambica International Corporation | DRP-4670 | Sep 4, 2028 | |
NoneSpironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Bell-Kenz Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-12383-01 | Jul 29, 2027 | |
NoneSpironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Bell-Kenz Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-12383-03 | Jul 29, 2027 | |
NoneSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-4662-05 | Sep 3, 2028 | |
NoneSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4662-06 | Sep 3, 2028 | |
Saphropir-GE25Spironolactone | 25 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17785 | Mar 11, 2031 | |
Solril-100Spironolactone | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4670-01 | Sep 4, 2028 | |
Solril-25Spironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Premier Pharmaceuticals Marketing Corp.Importer: Ambica International Corporation | DRP-4662-08 | Sep 3, 2028 | |
SpinofarSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Pharmacom DistributionImporter: Ambica International Corporation | DRP-4662-03 | Sep 3, 2028 | |
SpioreticSpironolactone | 50mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mepro Pharmaceuticals Private LimitedIndia | I.E Medica Inc.Importer: MedEthix Inc. | DRP-4711-01 | Oct 23, 2027 | |
SpireSpironolactone | 25mg Film-Coated TabletPVC/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mepro Pharmaceutical Private LimitedIndia | Corbridge Group Phils. Inc.Importer: Medethix Inc. | DRP-6798 | Jan 24, 2028 | |
SpireSpironolactone | 50 mg Film- Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | MEPRO Pharmaceutical Private LimitedIndia | Corbridge Group Phils., Inc.Importer: Medethix, Inc. | DRP-4711 | Oct 23, 2027 | |
Spirodan-25Spironolactone | 25mg TabletAlu/Pvc Blister Pack X 10'S (Box of 100's) | RxVAT-exempt | Baroque Pharmaceuticals Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18393 | Jun 30, 2031 | |
Spirodan-50Spironolactone | 50mg TabletAlu/Pvc Blister Pack X 10'S (Box of 100's) | RxVAT-exempt | Baroque Pharmaceuticals Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18394 | Jun 30, 2031 | |
SpirodenSpironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Cyden Medicale Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-7359-03 | Oct 4, 2031 | |
Spirodix-100Spironolactone | 100 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4670-02 | Sep 4, 2028 | |
Spirodix-25Spironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Euroasia Pharmaceuticals, IncImporter: Pharmakon Biotec Inc. | DRP-7359-01 | Oct 4, 2031 | |
SpirofarSpironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Bell-Kenz Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-7359 | Oct 4, 2036 | |
SpirofarSpironolactone | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Pharmakon Biotec Inc. | DRP-7361 | Oct 4, 2031 | |
Spirokind-25Spironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | I.E. Medica, Inc. | DRP-11430 | Mar 11, 2027 | |
Spirokind-50Spironolactone | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | I.E. Medica, Inc. | DRP-11429 | Mar 11, 2027 | |
SpirolinSpironolactone | 25 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Huazhong Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-16979 | Sep 3, 2030 | |
SpironexSpironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Bio Erixx Pharma DistributionImporter: Pharmakon Biotec Inc. | DRP-7359-15 | Oct 4, 2031 | |
SpirophilSpironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Philrx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-12383-02 | Jul 29, 2027 | |
SpirosSpironolactone | 100 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Next Chemical Enterprises | DRP-6413 | Mar 6, 2031 | |
SpirosSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Littman Drug CorporationImporter: Next Chemical Enterprises | DRP-7714 | Nov 15, 2031 | |
SpirotashSpironolactone | 25 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unicure Remedies Pvt. Ltd.India | Endure Medical, Inc.Importer: Ambica International Corporation | DRP-4662-09 | Sep 3, 2028 | |
SpirotrixSpironolactone | 25mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12383 | Jul 29, 2027 | |
Spirox 25Spironolactone | 25 mg Film Coated TabletAlu/Red PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | VEE Excel Drugs and Pharmaceuticals Private LimitedIndia | Airlife International Trading Corporation | DRP-18053 | Apr 30, 2031 | |
Spitone-25Spironolactone | 25 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | West-Coast Pharmaceutical Works Ltd.India | Cyden Medicale TradingImporter: Ambica International Corporation | DRP-10013 | Feb 16, 2038 | |
UnbrandedSpironolactone | 25 mg TabletAlu/Alu Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Reta DrugImporter: Pharmakon Biotec Inc. | DRP-7359-14 | Oct 4, 2031 | |
Urinasaph-SSpironolactone | 100 mg Film-Coated TabletAlu/ Clear PVC Blister Pack x 10's (Box of 30's, 60's, 90's and 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc., | DRP-13412 | Aug 27, 2030 | |
Urinasaph-SSpironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-13400 | Aug 19, 2030 | |
Urinasaph-SSpironolactone | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals LtdIndia | Nelpa Lifesciences, Inc. | DRP-16648 | Dec 19, 2030 | |
Zydactin 25Spironolactone | 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Maxtar Bio-GenicsIndia | Zydus Healthcare Philippines Inc.Importer: Pharmakon Biotec Inc. | DRP-7359-10 | Oct 4, 2031 | |
(no brand name)Spironolactone | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | I.E. Medica, Inc. | DRP-11428 | Mar 11, 2027 | |
(no brand name)Spironolactone | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | I.E. Medica, Inc. | DRP-11431 | Mar 11, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets: 25 mg round, light yellow, film-coated, with SEARLE and 1001 debossed on one side and ALDACTONE and 25 on the other side. Tablets: 50 mg oval, light orange, scored, film-coated, with SEARLE and 1041 debossed on the scored side and ALDACTONE and 50 on the other side. Tablets: 100 mg round, peach-colored, scored, film-coated, with SEARLE and 1031 debossed on the scored side and ALDACTONE and 100 on the other side. Tablets: 25 mg, 50 mg, and 100 mg (3)
Warnings/Precautions
- Hyperkalemia: Monitor serum potassium within one week of initiation and regularly thereafter (5.1).
- Hypotension and Worsening Renal Function: Monitor volume status and renal function periodically (5.2).
- Electrolyte and Metabolic Abnormalities: Monitor serum electrolytes, uric acid and blood glucose periodically (5.3).
- Gynecomastia: ALDACTONE can cause gynecomastia (5.4).
5.1 Hyperkalemia
5.1 Hyperkalemia ALDACTONE can cause hyperkalemia. This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions (7.1)].
Monitor serum potassium within 1 week of initiation or titration of ALDACTONE and regularly thereafter. More frequent monitoring may be needed when ALDACTONE is given with other drugs that cause hyperkalemia or in patients with impaired renal function. If hyperkalemia occurs, decrease the dose or discontinue ALDACTONE and treat hyperkalemia.
5.2 Hypotension and Worsening Renal Function
5.2 Hypotension and Worsening Renal Function Excessive diuresis may cause symptomatic dehydration, hypotension and worsening renal function, particularly in salt-depleted patients or those taking angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs).
Monitor volume status and renal function periodically.
5.3 Electrolyte and Metabolic Abnormalities
5.3 Electrolyte and Metabolic Abnormalities In addition to causing hyperkalemia, ALDACTONE can cause hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis, and hyperglycemia. Asymptomatic hyperuricemia can occur and rarely gout is precipitated. Monitor serum electrolytes, uric acid and blood glucose periodically.
5.4 Gynecomastia
5.4 Gynecomastia ALDACTONE can cause gynecomastia. In RALES, patients with heart failure treated with a mean dose of 26 mg of spironolactone once daily, about 9% of the male subjects developed gynecomastia. The risk of gynecomastia increases in a dose-dependent manner with an onset that varies widely from 1–2 months to over a year.
Gynecomastia is usually reversible.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Potassium supplements, potassium-containing salt substitutes, and potassium-raising drugs (ACE inhibitors, ARBs, finerenone/other MRAs, heparin/LMWH, trimethoprim) | Adjust or monitor | Severe hyperkalemia. | Usually stop potassium supplements in heart failure; check potassium when ACE inhibitor or ARB therapy changes. |
| Eplerenone | Avoid | Additive aldosterone blockade. | Contraindicated. |
| Lithium | Adjust or monitor | Reduced lithium clearance; toxicity. | Monitor lithium levels periodically. |
| NSAIDs | Adjust or monitor | Hyperkalemia, weaker diuretic and antihypertensive effect, and acute kidney injury risk. | Monitor potassium, kidney function and the diuretic response. |
| Cholestyramine | Adjust or monitor | Hyperkalemic metabolic acidosis reported. | Monitor; the label reports the effect. |
| Mitotane | Avoid | Spironolactone may block mitotane's effect. | Avoid concomitant use. |
| Digoxin assays | Minor | Interference with radioimmunoassays of digoxin. | Interpret digoxin levels with care. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5.1, 7.1).
- Lithium: Increased risk of lithium toxicity (7.2).
- NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of ALDACTONE (7.3).
- Digoxin: ALDACTONE can interfere with radioimmunologic assays of digoxin exposure (7.4).
- Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7.5).
- Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of ALDACTONE (7.6).
- Abiraterone: May increase prostate-specific antigen (PSA) levels (7.7).
- Mitotane: Avoid concomitant use of ALDACTONE and mitotane (7.8).
7.1 Drugs and Supplements Increasing Serum Potassium
7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of ALDACTONE with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start ALDACTONE [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving ALDACTONE. Examples of drugs that can increase potassium include:
- ACE inhibitors
- angiotensin receptor blockers
- non-steroidal anti-inflammatory drugs (NSAIDs)
- heparin and low molecular weight heparin
- trimethoprim
7.2 Lithium
7.2 Lithium Like other diuretics, ALDACTONE reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when ALDACTONE is coadministered [see Clinical Pharmacology (12.3)].
7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when ALDACTONE and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained [see Clinical Pharmacology (12.3)].
7.4 Digoxin
7.4 Digoxin Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.
7.5 Cholestyramine
7.5 Cholestyramine Hyperkalemic metabolic acidosis has been reported in patients given ALDACTONE concurrently with cholestyramine.
7.6 Acetylsalicylic Acid
7.6 Acetylsalicylic Acid Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when ALDACTONE and acetylsalicylic acid are used concomitantly, ALDACTONE may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained [see Clinical Pharmacology (12.3)].
7.7 Abiraterone
7.7 Abiraterone Spironolactone binds to the androgen receptor and may increase prostate-specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. Concomitant use of spironolactone and abiraterone is not recommended.
7.8 Mitotane
7.8 Mitotane Avoid concomitant use of ALDACTONE and mitotane. Spironolactone reduces mitotane plasma levels [see Clinical Pharmacology (12.3)].
Adverse reactions
Common
- Gynecomastia (most common; about 9% of men in RALES at a mean 26 mg/day)
Serious
- Hyperkalemia
- Hypotension and worsening kidney function from excessive diuresis
- Electrolyte and metabolic abnormalities (hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis, hyperglycemia, hyperuricemia)
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:
- Hyperkalemia [see Warnings and Precautions (5.1)]
- Hypotension and Worsening Renal Function [see Warnings and Precautions (5.2)]
- Electrolyte and Metabolic Abnormalities [see Warnings and Precautions (5.3)]
- Gynecomastia [see Warnings and Precautions (5.4]
- Impaired neurological function/ coma in patients with hepatic impairment, cirrhosis and ascites [see Use in Specific Populations (8.7)] The following adverse reactions associated with the use of spironolactone were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure. Digestive: Gastric bleeding, ulceration, gastritis, diarrhea and cramping, nausea, vomiting. Reproductive: Decreased libido, inability to achieve or maintain erection, irregular menses or amenorrhea, postmenopausal bleeding, breast and nipple pain. Hematologic: Leukopenia (including agranulocytosis), thrombocytopenia. Hypersensitivity: Fever, urticaria, maculopapular or erythematous cutaneous eruptions, anaphylactic reactions, vasculitis. Metabolism: Hyperkalemia, electrolyte disturbances [see Warnings and Precautions (5.1, 5.3)], hyponatremia, hypovolemia. Musculoskeletal: Leg cramps. Nervous system/psychiatric: Lethargy, mental confusion, ataxia, dizziness, headache, drowsiness. Liver/biliary: A very few cases of mixed cholestatic/hepatocellular toxicity, with one reported fatality, have been reported with spironolactone administration. Renal: Renal dysfunction (including renal failure). Skin: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, pruritis. The most common adverse reaction with ALDACTONE treatment is gynecomastia (5.4, 6). To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring parameters
- Serum potassium within 1 week of starting and regularly; kidney function and volume status; contraindicated with hyperkalemia, Addison's disease, eplerenone (label). Avoid potassium supplements and potassium-containing salt substitutes unless monitored (label 5.1). Kidney
- Serum potassium within 1 week of starting or titrating, then regularly (more often with other potassium-raising drugs)
- Electrolytes, uric acid and blood glucose periodically
- Kidney function and volume status
- Blood pressure
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on mechanism of action and findings in animal studies, spironolactone may affect sex differentiation of the male during embryogenesis (see Data). Rat embryofetal studies report feminization of male fetuses and endocrine dysfunction in females exposed to spironolactone in utero. Limited available data from published case reports and case series did not demonstrate an association of major malformations or other adverse pregnancy outcomes with spironolactone.
There are risks to the mother and fetus associated with heart failure, cirrhosis and poorly controlled hypertension during pregnancy (see Clinical Considerations). Because of the potential risk to the male fetus due to anti-androgenic properties of spironolactone and animal data, avoid spironolactone in pregnant women or advise a pregnant woman of the potential risk to a male fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively.
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Pregnant women with congestive heart failure are at increased risk for preterm birth. Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Clinical classification of heart disease may worsen with pregnancy and lead to maternal death.
Closely monitor pregnant patients for destabilization of their heart failure. Pregnant women with symptomatic cirrhosis generally have poor outcomes including hepatic failure, variceal hemorrhage, preterm delivery, fetal growth restriction and maternal death. Outcomes are worse with coexisting esophageal varices. Pregnant women with cirrhosis of the liver should be carefully monitored and managed accordingly.
Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Data Animal Data Teratology studies with ALDACTONE have been carried out in mice and rabbits at doses of up to 20 mg/kg/day.
On a body surface area basis, this dose in the mouse is substantially below the maximum recommended human dose and, in the rabbit, approximates the maximum recommended human dose. No teratogenic or other embryotoxic effects were observed in mice, but the 20 mg/kg dose caused an increased rate of resorption and a lower number of live fetuses in rabbits.
Because of its antiandrogenic activity and the requirement of testosterone for male morphogenesis, ALDACTONE may have the potential for adversely affecting sex differentiation of the male during embryogenesis. When administered to rats at 200 mg/kg/day between gestation days 13 and 21 (late embryogenesis and fetal development), feminization of male fetuses was observed.
Offspring exposed during late pregnancy to 50 and 100 mg/kg/day doses of ALDACTONE exhibited changes in the reproductive tract including dose-dependent decreases in weights of the ventral prostate and seminal vesicle in males, ovaries and uteri that were enlarged in females, and other indications of endocrine dysfunction, that persisted into adulthood. ALDACTONE has known endocrine effects in animals including progestational and antiandrogenic effects.
Mechanism of action
12.1 Mechanism of Action Spironolactone and its active metabolites are specific pharmacologic antagonists of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents that act more proximally in the renal tubule.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Aldosterone antagonist activity: Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and nephrotic syndrome. By competing with aldosterone for receptor sites, spironolactone provides effective therapy for the edema and ascites in those conditions. Spironolactone counteracts secondary aldosteronism induced by the volume depletion and associated sodium loss caused by active diuretic therapy.
Pharmacokinetics
Key PK parameters
| Bioavailability | Food raises AUC by about 95% |
|---|---|
| Time to peak | Spironolactone 2.6 hours; canrenone 4.3 hours |
| Half-life | Spironolactone 1.4 hours; canrenone 16.5 hours; TMS 13.8 hours; HTMS 15 hours |
| Half-life in kidney failure (ESKD) kidney | Not studied: renal impairment PK not specifically studied (label) |
| Protein binding | More than 90% (parent and metabolites) |
| Metabolism (CYP, transporters) | Rapid, extensive (canrenone, TMS, HTMS) |
| Active metabolites | Canrenone, 7-alpha-thiomethylspirolactone (TMS), HTMS |
| Renal excretion kidney | Metabolites mainly in urine, secondarily in bile |
| Dialyzability kidney | Not stated in label. |
Elimination The mean half-life of spironolactone is 1.4 hour.
The mean half-life values of its metabolites including canrenone, 7-α-(thiomethyl) spirolactone (TMS), and 6-β-hydroxy-7-α-(thiomethyl) spirolactone (HTMS) are 16.5, 13.8, and 15 hours, respectively.
In humans, the potencies of TMS and 7-α-thiospirolactone in reversing the effects of the synthetic mineralocorticoid, fludrocortisone, on urinary electrolyte composition were approximately a third relative to spironolactone.
Excretion: The metabolites are excreted primarily in the urine and secondarily in bile.
Patients with Hepatic Impairment: The terminal half-life of spironolactone has been reported to be increased in patients with cirrhotic ascites [see Use in Specific Populations (8.7) ] .
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption The mean time to reach peak plasma concentration of spironolactone and the active metabolite, canrenone, in healthy volunteers is 2.6 and 4.3 hours, respectively. Effect of food: Food increased the bioavailability of spironolactone (as measured by AUC) by approximately 95.4%. Patients should establish a routine pattern for taking ALDACTONE with regard to meals [see Dosage and Administration (2.1)].
Distribution Spironolactone and its metabolites are more than 90% bound to plasma proteins. Elimination The mean half-life of spironolactone is 1.4 hour. The mean half-life values of its metabolites including canrenone, 7-α-(thiomethyl) spirolactone (TMS), and 6-β-hydroxy-7-α-(thiomethyl) spirolactone (HTMS) are 16.5, 13.8, and 15 hours, respectively.
Metabolism: Spironolactone is rapidly and extensively metabolized. Metabolites can be divided into two main categories: those in which sulfur of the parent molecule is removed (e.g., canrenone) and those in which the sulfur is retained (e.g., TMS and HTMS). In humans, the potencies of TMS and 7-α-thiospirolactone in reversing the effects of the synthetic mineralocorticoid, fludrocortisone, on urinary electrolyte composition were approximately a third relative to spironolactone.
However, since the serum concentrations of these steroids were not determined, their incomplete absorption and/or first-pass metabolism could not be ruled out as a reason for their reduced in vivo activities. Excretion: The metabolites are excreted primarily in the urine and secondarily in bile. Specific Populations The impact of age, sex, race/ethnicity, and renal impairment on the pharmacokinetics of spironolactone have not been specifically studied.
Patients with Hepatic Impairment: The terminal half-life of spironolactone has been reported to be increased in patients with cirrhotic ascites [see Use in Specific Populations (8.7)]. Drug Interaction Studies: Drugs and Supplements Increasing Serum Potassium: Concomitant administration of ALDACTONE with potassium supplementation, salt substitutes containing potassium, a diet rich in potassium, or drugs that can increase potassium, including ACE inhibitors, angiotensin II antagonists, non-steroidal anti-inflammatory drugs (NSAIDs), heparin and low molecular weight heparin, may lead to severe hyperkalemia [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].
Lithium: ALDACTONE reduces the renal clearance of lithium, inducing a high risk of lithium toxicity [see Drug Interactions (7.2)]. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of loop, potassium-sparing, and thiazide diuretics [see Drug Interactions (7.3)].
Acetylsalicylic acid: A single dose of 600 mg of acetylsalicylic acid inhibited the natriuretic effect of spironolactone, which was hypothesized be due to inhibition of tubular secretion of canrenone, causing decreased effectiveness of spironolactone [see Drug Interactions (7.6)]. Mitotane: The effect of concomitant spironolactone on the pharmacokinetics of mitotane has not been studied; however, patients exhibited significantly lower mitotane levels compared to those who did not receive concomitant spironolactone despite receiving higher mitotane doses [see Drug Interactions (7.8)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Spironolactone 25 mg Tablet | ₱4.71–₱15.00Reference ₱9.20 | per tablet | DPRI procurement range |
| Spironolactone 50 mg Tablet | ₱8.50–₱36.28Reference ₱24.96 | per tablet | DPRI procurement range |
| Spironolactone 100 mg Tablet | ₱31.28–₱33.00Reference ₱31.28 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Spironolactone (K-sparer) |
| PNF listing | Oral: 25 mg, 50 mg and 100 mg tabletRestrictions: Limited indications or narrow spectrum of activity (PNF code 2); List B: in vivo bioequivalence studies required (PNF code B) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Aldactone · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 25, November 28, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Pfizer Laboratories Div Pfizer Inc. (2025). Aldactone (spironolactone) [Prescribing information; US FDA-approved label, NDA012151, set ID 0fed2822-3a03-4b64-9857-c682fcd462bc, version effective November 28, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fed2822-3a03-4b64-9857-c682fcd462bc
- Walsh, M., Collister, D., Gallagher, M., Mark, P. B., de Zoysa, J. R., Tyrwhitt, J., Tennankore, K., Reis, G., Xavier, D., Liu, W. J., Zuo, L., Wang, A. Y., Félix, C., Sola, L., Arici, M., Villanueva, R., Jha, V., Précoma, D., Rabbat, C. G., ... Devereaux, P. J. (2025). Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): An international, parallel-group, randomised controlled trial. The Lancet, 406(10504), 695–704. https://doi.org/10.1016/S0140-6736(25)01198-5
- Rossignol, P., Zannad, F., Massy, Z., et al. (2025). Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): A multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. The Lancet, 406(10504), 705–718. https://doi.org/10.1016/S0140-6736(25)01194-8
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .



